🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumors Patients

    phase 1 small molecule active

    1 trial

  2. SSGJ-709

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Malignant Tumors

    phase 1 small molecule active

    1 trial

  3. SSS11

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 mab active

    1 trial

  4. SSS17

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Anemia in Chronic Kidney Diseases

    phase 1 small molecule active

    2 trials

  5. SSS17

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Healthy Subjects (HS)

    phase 1 small molecule completed

    1 trial

  6. SSS39

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Safety and Tolerability in Healthy Volunteers

    phase 1 small molecule active

    1 trial

  7. SSS55

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Safety Issues

    phase 1 small molecule active

    1 trial

  8. SSS59

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Malignant Tumors

    phase 1 small molecule active

    1 trial

  9. SSS67 Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Healthy

    phase 1 small molecule active

    1 trial

  10. STRO-001

    SUTRO BIOPHARMA, INC.

    B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  11. STRO-002

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    2 trials

  12. STRO-004

    SUTRO BIOPHARMA, INC.

    Head and Neck Squamous Cell Carcinoma HNSCC

    phase 1 small molecule active

    1 trial

  13. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  14. Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Multiple Sclerosis

    phase 1 other active

    1 trial

  15. Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

    Lacuna Pharma Pty Ltd

    Glaucoma

    phase 1 other active

    1 trial

  16. Safety, Tolerability and Pharmacokinetic Profile of TPT0301 in Healthy Volunteers

    Alphapharm Pty Ltd

    adjunctive neuropathic pain

    phase 1 other active

    1 trial

  17. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.

    NEUROCRINE BIOSCIENCES INC

    Movement disorders

    phase 1 other active

    1 trial

  19. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults

    NEUROCRINE BIOSCIENCES INC

    Neurological and neuropsychiatric conditions

    phase 1 other active

    1 trial

  20. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  21. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  22. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Food Effect

    phase 1 small molecule completed

    1 trial

  23. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  24. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Evaluation of Abuse Potential of Sativex

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources